These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 26071795)

  • 81. Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?
    Yang H; Zhou L; Wang S; Cao Y; Tong F; Liu P; Zhou B; Cheng L; Liu M; Liu H; Xie F; Guo J; Wang S; Peng Y
    Medicine (Baltimore); 2018 Oct; 97(40):e12690. PubMed ID: 30290661
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy.
    Tanioka M; Shimizu C; Yonemori K; Yoshimura K; Tamura K; Kouno T; Ando M; Katsumata N; Tsuda H; Kinoshita T; Fujiwara Y
    Br J Cancer; 2010 Jul; 103(3):297-302. PubMed ID: 20606681
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis.
    Melichar B; Hornychová H; Kalábová H; Bašová H; Mergancová J; Urminská H; Jandík P; Cervinka V; Laco J; Ryška A
    Med Oncol; 2012 Dec; 29(4):2577-85. PubMed ID: 22392196
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Nov; 7():203. PubMed ID: 17976237
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response.
    Stevens W; Farrow IM; Georgiou L; Hanby AM; Perren TJ; Windel LM; Wilson DJ; Sharma N; Dodwell D; Hughes TA; Dall BJ; Buckley DL
    Br J Radiol; 2021 Jul; 94(1123):20201396. PubMed ID: 34106751
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Predictive Value of IHC4 Score for Pathological Response to Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer.
    Elsamany S; Elmorsy S; Alzahrani A; Rasmy A; Abozeed WN; Mohammed AA; Sherisher MA; Abbas MM; Mashhour M
    Asian Pac J Cancer Prev; 2015; 16(17):7975-9. PubMed ID: 26625828
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Complete pathological response in patients with HER2 positive breast cancer treated with neoadjuvant therapy in Colombia.
    Rodríguez M; González DM; El-Sharkawy F; Castaño M; Madrid J
    Biomedica; 2023 Sep; 43(3):396-405. PubMed ID: 37871573
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.
    Hamy AS; Belin L; Bonsang-Kitzis H; Paquet C; Pierga JY; Lerebours F; Cottu P; Rouzier R; Savignoni A; Lae M; Reyal F
    Br J Cancer; 2016 Jan; 114(1):44-52. PubMed ID: 26657653
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer.
    Won HS; Kim YS; Kim JS; Chang ED; Na SJ; Whang IY; Lee DS
    Korean J Intern Med; 2020 Nov; 35(6):1489-1496. PubMed ID: 32069523
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Human Epidermal Growth Factor 2-positive Breast Cancer with Mammographic Microcalcification: Relationship to Pathologic Complete Response after Neoadjuvant Chemotherapy.
    Mazari FAK; Sharma N; Dodwell D; Horgan K
    Radiology; 2018 Aug; 288(2):366-374. PubMed ID: 29786482
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer.
    Wu J; Li S; Jia W; Su F
    J Cancer Res Clin Oncol; 2011 Oct; 137(10):1505-10. PubMed ID: 21830158
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Prediction of pathological response to neoadjuvant chemotherapy in breast cancer patients by imaging.
    Kaise H; Shimizu F; Akazawa K; Hasegawa Y; Horiguchi J; Miura D; Kohno N; Ishikawa T
    J Surg Res; 2018 May; 225():175-180. PubMed ID: 29605029
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study.
    Winter MC; Wilson C; Syddall SP; Cross SS; Evans A; Ingram CE; Jolley IJ; Hatton MQ; Freeman JV; Mori S; Holen I; Coleman RE
    Clin Cancer Res; 2013 May; 19(10):2755-65. PubMed ID: 23515409
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.
    Ali HR; Dariush A; Provenzano E; Bardwell H; Abraham JE; Iddawela M; Vallier AL; Hiller L; Dunn JA; Bowden SJ; Hickish T; McAdam K; Houston S; Irwin MJ; Pharoah PD; Brenton JD; Walton NA; Earl HM; Caldas C
    Breast Cancer Res; 2016 Feb; 18(1):21. PubMed ID: 26882907
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Dynamic contrast-enhanced MR imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancer.
    Jia Q; Xu J; Jiang W; Zheng M; Wei M; Chen J; Wang L; Huan Y
    Int J Med Sci; 2013; 10(2):110-8. PubMed ID: 23329881
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Pre-treatment haemoglobin levels and the prediction of response to neoadjuvant chemotherapy in breast cancer.
    Beresford MJ; Burcombe R; Ah-See ML; Stott D; Makris A
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):453-8. PubMed ID: 16909968
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Morphological and pathological response in primary systemic therapy of patients with breast cancer and the prediction of disease free survival: a single center observational study.
    Szentmartoni G; Tokes AM; Tokes T; Somlai K; Szasz AM; Torgyík L; Kulka J; Dank M
    Croat Med J; 2016 Apr; 57(2):131-9. PubMed ID: 27106355
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer.
    Skarping I; Förnvik D; Sartor H; Heide-Jørgensen U; Zackrisson S; Borgquist S
    BMC Cancer; 2019 Dec; 19(1):1272. PubMed ID: 31888552
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Neoadjuvant Chemotherapy Use for Nonmetastatic Breast Cancer at Five Public South African Hospitals and Impact on Time to Initial Cancer Therapy.
    O'Neil DS; Nietz S; Buccimazza I; Singh U; Čačala S; Stopforth LW; Joffe M; Jacobson JS; Neugut AI; Crew KD; Ruff P; Cubasch H
    Oncologist; 2019 Jul; 24(7):933-944. PubMed ID: 30518615
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment.
    Al-Khanbashi M; Caramuta S; Alajmi AM; Al-Haddabi I; Al-Riyami M; Lui WO; Al-Moundhri MS
    PLoS One; 2016; 11(4):e0152032. PubMed ID: 27064979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.